Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: A population pharmacokinetic analysis

British Journal of Clinical Pharmacology

Volumn 79, Issue 5, 2015, Pages 789-800

  Gupta, Neeraj ^a   Zhao, Yuan ^a   Hui, Ai Min ^a   Esseltine, Dixie Lee ^a   Venkatakrishnan, Karthik ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

ixazomib; population PK; proteasome inhibitor; renal insufficiency

Indexed keywords

IXAZOMIB; ANTINEOPLASTIC AGENT; BORON DERIVATIVE; GLYCINE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; BODY SURFACE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; HUMAN; MAJOR CLINICAL STUDY; PERIPHERAL VOLUME OF DISTRIBUTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; AGED; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BIOLOGICAL MODEL; BLOOD; COMPUTER SIMULATION; DOSE RESPONSE; FEASIBILITY STUDY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY SURFACE AREA; BORON COMPOUNDS; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; GLYCINE; HUMANS; INJECTIONS, INTRAVENOUS; LYMPHOMA; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; PROTEASE INHIBITORS; YOUNG ADULT;

EID: 84928317602     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12542     Document Type: Article

References (45)

1. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL,. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947-959.
2. Millennium: The Takeda Oncology Company. VELCADE® (bortezomib) for injection. Prescribing information. October 2012, Revision 15. 2013. Available at http://www.velcade.com/files/PDFs/VELCADE-PRESCRIBING-INFORMATION.pdf (last accessed 25 September 2014).
3. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL,. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431-440.
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC,. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
5. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG,. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
6. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG,. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013; 31: 448-455.
7. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL,. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011; 12: 773-784.
8. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL,. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118: 865-873.
9. Onyx Pharmaceuticals. Kyprolis (carfilzomib) for Injection. Prescribing information. 2014. Revised 07/2012. Available at http://www.kyprolis.com/Areas/Hcp/content/pdfs/PI.pdf (last accessed 20 December 2013).
10. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS,. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119: 5661-5670.
11. McBride A, Ryan PY,. Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther 2013; 13: 339-358.
12. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J,. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010; 70: 1970-1980.
13. Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van NB, Janz S,. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 2011; 17: 7313-7323.
14. Assouline S, Chang JE, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui AM, Yu J, Gupta N, Di Bacco A, Shou Y, Martin P,. Results of a phase 1 dose-escalation study of once-weekly MLN9708, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. ASH Annual Meeting Abstracts 2012; 120: 3646.
15. Richardson PG, Baz R, Wang L, Jakubowiak AJ, Berg D, Liu G, Gupta N, Di Bacco A, Hui AM, Lonial S,. Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study. ASH Annual Meeting Abstracts 2011; 118: 301.
16. Kumar S, Bensinger W, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui A-M, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R,. Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): results from a phase I study after full enrollment. ASCO Meeting Abstracts 2013; 31: abstract 8514.
17. Rodler ET, Infante JR, Siu LL, Smith DC, Sullivan D, Vlahovic G, Gomez-Navarro J, Liu G, Blakemore S, Thompson JA,. First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies. ASCO Meeting Abstracts 2010; 28: 3071.
18. Gupta N, Noe D, Liu G, Berg D, Kalebic T, Shou Y, Hui A-M, Venkatakrishnan K,. Clinical pharmacokinetics of intravenous and oral MLN9708: pooled analysis from monotherapy and combination studies across various indications. Clin Pharmacol Ther 2013; 93 (Suppl. 1) (s32): abstract PI-51.
19. Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A,. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007; 12: 913-923.
20. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A,. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002; 94: 1883-1888.
21. Beumer JH, Chu E, Salamone SJ,. Body-surface area-based chemotherapy dosing: appropriate in the 21st century? J Clin Oncol 2012; 30: 3896-3897.
22. Munar MY, Singh H,. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician 2007; 75: 1487-1496.
23. Nolin TD, Naud J, Leblond FA, Pichette V,. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008; 83: 898-903.
24. Sun H, Frassetto L, Benet LZ,. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006; 109: 1-11.
25. Verbeeck RK, Musuamba FT,. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009; 65: 757-773.
26. Dimopoulos MA, Terpos E,. Renal insufficiency and failure. Hematology Am Soc Hematol Educ Program 2010; 2010: 431-436.
27. Clark AD, Shetty A, Soutar R,. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999; 13: 79-90.
28. Beal SL, Sheiner LB, NONMEM Project Group. NONMEM User's Guide. San Francisco, USA: University of California, 1998.
29. Savic RM, Karlsson MO,. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 558-569.
30. Karlsson MO, Sheiner LB,. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21: 735-750.
31. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
32. Karlsson MO, Savic RM,. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 17-20.
33. Yano Y, Beal SL, Sheiner LB,. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-192.
34. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC,. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-172.
35. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV,. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119: 4375-4382.
36. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC,. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
37. Gupta N, Riordan WJ, Berger A, Liu G, Berg D, Kalebic T, Hui A-M, Blakemore S,. Clinical pharmacokinetics (PK)/pharmacodynamics (PD) of intravenous (IV) and oral (PO) MLN9708, an investigational proteasome inhibitor, in four phase 1 monotherapy studies. Haematologica 2011; 96: s88.
38. de Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A,. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 2004; 54: 105-112.
39. Bins S, Ratain MJ, Mathijssen RH,. Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin Pharmacol Ther 2014; 95: 361-364.
40. Chatelut E, Puisset F,. The scientific basis of body surface area-based dosing. Clin Pharmacol Ther 2014; 95: 359-361.
41. Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP, Jr, McLeod HL, Davidson NE, Wolff AC,. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat 2013; 139: 135-143.
42. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San MJ,. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976-4984.
43. Quach H, Prince HM, Spencer A,. Managing multiple myeloma in the elderly: are we making progress? Expert Rev Hematol 2011; 4: 301-315.
44. Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H, III, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke LL, Acharya M, Zannikos P, Keith SA,. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 2011; 67: 57-67.
45. Di Bacco A, Berger A, Gupta N, Gao F, Blakemore S, Qian M, Chen S, Stringer B, Yang Y, Liu R, Tirrell S, Bowman D, Smith DC, Sullivan D, Infante JR, Kauh JS, Siu LL, Vlahovic G, Thompson JA, Kalebic T,. Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors. ASCO Meeting Abstracts 2012; 30: 3077.